Literature DB >> 7550108

Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5'-terminal with poly(ethylene glycol).

T Kawaguchi1, H Asakawa, Y Tashiro, K Juni, T Sueishi.   

Abstract

Oligodeoxynucleotide (ODN) composed of 15 nucleotides was modified at 5'-terminal phosphate with hexylamine linker and chemically activated poly(ethylene glycol). This derivative showed improved characteristics in terms of enzymatic stability, binding activity, and in vivo retention in mouse. The data are discussed in comparison with those of corresponding unmodified and phosphorothioate ODNs.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7550108     DOI： 10.1248/bpb.18.474

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN： 0918-6158            Impact factor:   2.233


  13 in total

1.  Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.

Authors:  William M Rockey; Frank J Hernandez; Sheng-You Huang; Song Cao; Craig A Howell; Gregory S Thomas; Xiu Ying Liu; Natalia Lapteva; David M Spencer; James O McNamara; Xiaoqin Zou; Shi-Jie Chen; Paloma H Giangrande
Journal:  Nucleic Acid Ther       Date:  2011-10       Impact factor: 5.486

Review 2.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  PEGylation of therapeutic oligonucletides: From linear to highly branched PEG architectures.

Authors:  Xueguang Lu; Ke Zhang
Journal:  Nano Res       Date:  2018-07-06       Impact factor: 8.897

4.  CpG-PEG Conjugates and their Immune Modulating Effects after Systemic Administration.

Authors:  Caixing Wu; Xiaofei Xiang; Yang Yue; Lin Li; Yesen Li; Chong Zhang; Yuhong Xu
Journal:  Pharm Res       Date:  2018-03-02       Impact factor: 4.200

Review 5.  Aptamers as targeted therapeutics: current potential and challenges.

Authors:  Jiehua Zhou; John Rossi
Journal:  Nat Rev Drug Discov       Date:  2016-11-03       Impact factor: 84.694

Review 6.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

7.  Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.

Authors:  Shashi Gupta; Masao Hirota; Sheela M Waugh; Ikuo Murakami; Tomoki Suzuki; Masahiro Muraguchi; Masafumi Shibamori; Yuichi Ishikawa; Thale C Jarvis; Jeffrey D Carter; Chi Zhang; Bharat Gawande; Michael Vrkljan; Nebojsa Janjic; Daniel J Schneider
Journal:  J Biol Chem       Date:  2014-01-12       Impact factor: 5.157

Review 8.  Aptamers in diagnostics and treatment of viral infections.

Authors:  Tomasz Wandtke; Joanna Woźniak; Piotr Kopiński
Journal:  Viruses       Date:  2015-02-16       Impact factor: 5.048

Review 9.  Fit for the Eye: Aptamers in Ocular Disorders.

Authors:  Daniel W Drolet; Louis S Green; Larry Gold; Nebojsa Janjic
Journal:  Nucleic Acid Ther       Date:  2016-01-12       Impact factor: 5.486

10.  Synthesis by High-Efficiency Liquid-Phase (HELP) Method of Oligonucleotides Conjugated with High-Molecular Weight Polyethylene Glycols (PEGs).

Authors:  G M Bonora; S Zaramella; F M Veronese
Journal:  Biol Proced Online       Date:  1998-05-14       Impact factor: 3.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.